title: Search for correlation of CD8 T cell response to Epstein-Barr virus with clinical status in rheumatoid arthritis: a 15 month followup pilot study.
abstract: OBJECTIVE
  To assess in a longitudinal 15 month followup study the CD8 T cell response to immunodominant Epstein-Barr virus (EBV) antigens of 17 patients with rheumatoid arthritis (RA); and to seek an association between these responses and both clinical activity/severity of RA and a qualitative PCR for EBV in peripheral blood.
  
  
  METHODS
  At each patient's visit every 3 months: (1) RA activity was assessed for Disease Activity Score (DAS-28); (2) a qualitative PCR for EBV was performed; (3) CD8 T cell response to EBV epitopes was screened in peripheral blood, using an autopresentation assay of 13 EBV peptides previously identified as immunodominant targets in RA synovia. Activation of anti-EBV CD8 T cells was evaluated by measuring the release of tumor necrosis factor-a.
  
  
  RESULTS
  The semiquantitative CD8 T cell response to EBV roughly paralleled RA clinical activity in only 4/17 patients. No clear association could be found between positive PCR for EBV (performed at least once in 10/17 patients) and RA activity/severity or fatigue. Reactivity was not qualitatively broader in samples where PCR for EBV proved positive, and most often focused on one or 2 EBV antigens. However, these antigens differed between patients, as did the magnitude of CD8 T cell response to immunodominant antigens at different timepoints for the same patient.
  
  
  CONCLUSIONS
  The CD8 T cell response to EBV paralleled clinical activity in only 4/17 patients. Our pilot study does not support the hypothesis that this CD8 response contributes to RA activity/flares, although the quantitative variations in the pattern of this reactivity over time confirmed that control of EBV manifestations was difficult in most patients with RA.
authors.affiliation: Rheumatology Unit, CHU Nantes, Nantes, France. jeanmarie.berthelot@chu-nantes.fr
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Berthelot
authors.forename: Xavier
authors.initials: X
authors.lastname: Saulquin
authors.forename: Marianne
authors.initials: M
authors.lastname: Coste-Burel
authors.forename: Marie A
authors.initials: MA
authors.lastname: Peyrat
authors.forename: Klara
authors.initials: K
authors.lastname: Echasserieau
authors.forename: Marc
authors.initials: M
authors.lastname: Bonneville
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Houssaint
mesh_terms: D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology*; D020031:Epstein-Barr Virus Infections / Q000276:immunology*; D005260:Female; D005500:Follow-Up Studies; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000276:immunology*; D006801:Humans; D016130:Immunophenotyping; D008137:Longitudinal Studies; D008875:Middle Aged; D010865:Pilot Projects; D016133:Polymerase Chain Reaction